New imaging study reveals how drug tames Crohn's inflammation
NCT ID NCT05642247
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at 150 adults with Crohn's disease to see if advanced imaging could predict how well the drug Ustekinumab controls inflammation. Researchers measured changes in the gut wall and compared them to standard tests. The goal was to improve treatment monitoring for this chronic condition.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
150 people
The number who actually took part.
- Started
-
Jul 2022
- Finished
-
Jan 2023
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
January 2020 to June 2022 CD patients in the IBD center of Sixth Affiliated Hospital of Sun Yat-Sen University, who were treated with Ustekinumab.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Inpatients with Crohn's disease diagnosed in the IBD center of Sixth Affiliated Hospital of Sun Yat-Sen University from January 2020 to June 2022 * Treated with Ustekinumab and followed up regularly for 20 weeks * Complete pre-treatment cross-sectional imaging data (CTE/MRE and US) Exclusion Criteria: * The diagnosis is not clear * Under the age of 18 * Lack of endoscopic and pathological data
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Biologics are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
the Sixth Affiliated Hospital of Sun Yat-Sen University
Guangzhou, Guangdong, 501655, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Mini-Guts in a dish: scientists probe why IBD tissue struggles to heal
- Can immune aging blood tests predict which older IBD patients thrive on advanced therapies?
- Can a cheap Anti-Inflammatory drug calm ulcerative colitis?
- Can early symptom relief predict who stays on IBD biologic?
- Can a liquid diet calm Crohn's in kids?
- Which IBD therapy works best for kids? researchers compare two approaches